WO2020230331A1 - Promoteur de l'expression d'apj - Google Patents

Promoteur de l'expression d'apj Download PDF

Info

Publication number
WO2020230331A1
WO2020230331A1 PCT/JP2019/019573 JP2019019573W WO2020230331A1 WO 2020230331 A1 WO2020230331 A1 WO 2020230331A1 JP 2019019573 W JP2019019573 W JP 2019019573W WO 2020230331 A1 WO2020230331 A1 WO 2020230331A1
Authority
WO
WIPO (PCT)
Prior art keywords
apj
skin elasticity
expression
skin
apj expression
Prior art date
Application number
PCT/JP2019/019573
Other languages
English (en)
Japanese (ja)
Inventor
美加 加治屋
健太朗 加治屋
上田　有紀
綾野 松尾
Original Assignee
株式会社 資生堂
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社 資生堂 filed Critical 株式会社 資生堂
Priority to CN201980096460.XA priority Critical patent/CN113825492A/zh
Priority to JP2021519240A priority patent/JPWO2020230331A1/ja
Priority to PCT/JP2019/019573 priority patent/WO2020230331A1/fr
Publication of WO2020230331A1 publication Critical patent/WO2020230331A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/78—Saururaceae (Lizard's-tail family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Definitions

  • the present invention relates to an APJ expression promoter.
  • Skin elasticity has a great influence on the appearance age and appearance, and maintaining and improving skin elasticity is a major cosmetic issue.
  • many studies have been conducted on the matrix of the dermis layer such as collagen, elastin, and hyaluronic acid.
  • the amount of collagen in the dermis layer has a large effect.
  • Conventional cosmetological methods have focused on increasing elastic fibers by activating dermal fibroblasts in order to achieve improvement in skin elasticity, and have the effect of activating dermal fibroblasts and promoting collagen production. Ingredients have been discovered and applied to cosmetics.
  • Japanese Patent No. 5808769 Japanese Unexamined Patent Publication No. 2012-20942 Japanese Unexamined Patent Publication No. 2013-209339 International Publication No. 2012/133825 JP-A-2018-172410 Special Table 2019-501899 International Publication No. 2007/072980 Japanese Patent No. 5648149
  • An object of the present invention is to provide a method for screening a substance that improves skin elasticity and a substance that has a skin elasticity improving action by a mechanism different from conventional skin elasticity improving agents and methods.
  • the present inventors have stabilized skin blood vessels by enhancing the expression of APJ, improved their functions, and / or suppressed the decrease of skin blood vessels due to aging.
  • We have discovered that the elasticity of the skin is improved, and further discovered a novel substance that promotes the expression of APJ, leading to the present invention.
  • the present invention relates to the following invention: (1) APJ expression promoter for improving skin elasticity.
  • An APJ expression promoter consisting of one or more crude drugs selected from the group consisting of Houttuynia cordata extract, Sakura leaf extract, and neem leaf extract.
  • (Four) A screening method for skin elasticity improving agents using APJ expression as an index.
  • Culturing a biological sample in a medium containing a candidate drug To measure APJ expression in a biological sample, and to determine a candidate drug as a substance having a skin elasticity improving effect when APJ expression is increased compared to a control.
  • the screening method according to (4).
  • the APJ expression promoter of the present invention can promote the expression of APJ.
  • APJ expression promoters containing one or more crude drugs selected from the group consisting of Houttuynia cordata extract, Sakura leaf extract, and neem leaf extract are effective in improving skin elasticity through stabilization of blood vessels.
  • a substance having an action of improving skin elasticity can be selected.
  • the skin elasticity improver selected by the screening method of the present invention improves skin elasticity through the stabilization of blood vessels by promoting the expression of APJ. By improving skin elasticity, skin problems such as wrinkles and sagging can be improved.
  • FIG. 2 is a photomicrograph of an angiogenesis model showing the localization of blood vessels (green) stained with anti-PECAM-1 / CD31 antibody and type I collagen (red) stained with anti-type I Collagen antibody.
  • the sound velocity (hardness) value (m / s) of a human skin section is measured by an ultrasonic sound velocity microscope, and the obtained image and the immunostained image that visualizes the blood vessel (red) of the same section are superimposed. It is a combination. As typical examples, young people (20 years old) and middle-aged people (50 years old) are shown.
  • FIG. 4 is a graph showing the relationship between the collagen concentration (mg / ml) and the storage elastic modulus G'(Pa).
  • FIG. 5 is a graph showing the relationship between collagen concentration (mg / ml) and contact force (mN).
  • Figure 6 shows a 3D angiogenic dermis model cultured in a collagen gel at each concentration (mg / ml) stained with anti-PECAM-1 / CD31 antibody to stain blood vessels (green) and with Cy3 ⁇ SMA antibody to stain pericytes (pericytes). It is a micrograph which visualized red).
  • the left figure of FIG. 7 is a graph showing the relationship between the collagen gel concentration and the mRNA expression level of APJ in the vascular endothelial cells cultured in the collagen gel having each concentration, and when the gel concentration is 0 mg / ml (-). It is shown as a relative value (%) with the expression level as 100.
  • FIG. 8 shows an outline of creating a 3D angioplasty dermis model in which APJ high expression vector is transfected and APJ is highly expressed.
  • FIG. 9 is a schematic diagram showing the concept of the relationship between skin elasticity, APJ expression, and blood vessel stabilization derived from the present application.
  • FIG. 10 shows the expression of APJ when using Houttuynia cordata extract, Sakura leaf extract, and Neem leaf extract as a relative value (%) when the control is 100.
  • * and ** indicate that there is a significant difference from the control by Student's t-test (* p ⁇ 0.05, ** p ⁇ 0.01).
  • APJ also known as AGTRL1: Angiotensin receptorlike1
  • AGTRL1 Angiotensin receptorlike1
  • APJ expression has been shown to be involved in myocardial contraction in the heart, regulation of vasopressin expression in the nervous system, stability of blood vessels and lymph vessels, and regulatory mechanisms of body fluids.
  • vascular endothelial cells and parietal cells it has been reported that it is expressed in vascular endothelial cells and parietal cells, and is considered to play an important role in angiogenesis of the cardiovascular system and peripheral blood vessels.
  • Non-Patent Documents 1 to 7 Non-Patent Documents 1 to 5).
  • the relationship between skin elasticity and APJ expression is not known from the findings so far.
  • the present inventors have found that promoting the expression of APJ stabilizes blood vessels and synthesizes collagen around the blood vessels, that is, improves skin elasticity.
  • the expression of APJ changes according to the physical properties of the surrounding environment such as matrix elasticity, which is greatly involved in skin elasticity.
  • the expression of APJ in blood vessels and the physical properties such as skin elasticity due to collagen synthesis are closely interacted with each other, and the expression of APJ is enhanced in vivo according to the physical properties of the surrounding matrix environment, and as a result, the vascular structure is stabilized.
  • Discovered a mechanism by which collagen synthesis is promoted in the surroundings and the skin maintains proper elasticity.
  • the present invention is based on the findings of such inventors, and relates to an APJ expression promoter for improving skin elasticity.
  • the APJ expression promoter of the present invention comprises or comprises one or more crude drugs selected from the group consisting of Houttuynia cordata extract, Sakura leaf extract, and neem leaf extract.
  • the substance is not limited to these as long as it can promote the expression of APJ, and for example, APJ activators as described in Patent Documents 3, 4, 7, Non-Patent Document 4, etc. may be used. Good.
  • Houttuynia cordata also known as Houttuynia, is a perennial plant belonging to the genus Houttuynia, which is widely distributed in various Asian regions such as Japan, China, and Vietnam. Plants such as leaves, stems, flowers and roots are used for medicinal purposes such as diuresis, hypertension and arteriosclerosis.
  • Houttuynia cordata extract refers to an extract extracted from the plant body of Houttuynia cordata, especially the above-ground part.
  • Plum leaf refers to the leaves of plants belonging to the genus Plumus, such as Yoshino cherry tree (Prunus yedoensis Matsum.), Prunus lannesiana var. Speciosa., And Prunus serrulata.
  • the genus Plum is a deciduous broad-leaved tree of the Rosaceae family found in various parts of Japan, East Asia, North America, etc.
  • Sakura leaf is known to have a moisturizing effect, a whitening effect, an anti-inflammatory effect and the like.
  • Plum leaf extract refers to an extract obtained by extracting leaves of the genus Plum.
  • Neem (Azadirachta indica) is a tree of the family Meliaceae native to India, also known as Neem tree. Neem is used in Ayurveda and the like for the purpose of bactericidal action, moisturizing action and the like in India, Sri Lanka and the like. Neem leaf extract refers to an extract obtained by extracting neem leaves.
  • the above-mentioned plant extract may be commercially available as a cosmetic raw material or a health food material, or may be obtained by a conventional method.
  • the extraction method is not particularly limited, but an extraction method using a solvent is preferable.
  • the raw material plant can be obtained by dipping or heating at room temperature or heating with an extraction solvent, and then filtering and concentrating.
  • the plant body can be used as it is, it is possible to extract the active ingredient in a short time with high extraction efficiency under mild conditions by crushing it into granules or powder and using it for extraction.
  • the extraction temperature is not particularly limited, and may be appropriately set according to the particle size of the pulverized product, the type of solvent, and the like.
  • the extraction time is not particularly limited, and may be appropriately set according to the particle size of the pulverized product, the type of solvent, the extraction temperature, and the like. Further, at the time of extraction, stirring may be performed, the mixture may be allowed to stand without stirring, or ultrasonic waves may be applied.
  • any solvent can be used as long as it is usually used for extraction.
  • an aqueous solvent such as water, physiological saline, a phosphate buffer solution, a borate buffer solution, or an organic solvent such as ethanol can be used.
  • Alcohols such as propylene glycol, 1,3-butylene glycol and glycerin, hydrous alcohols, chloroform, dichloroethane, carbon tetrachloride, acetone, ethyl acetate, hexane and the like can be used alone or in combination.
  • the active ingredient is extracted and dissolved in the solvent.
  • the solvent containing the extract may be used as it is, or may be used after being subjected to conventional purification treatments such as sterilization, washing, filtration, decolorization, and deodorization. Further, if necessary, it may be concentrated by freeze-drying or diluted with an arbitrary solvent before use. Further, the solvent may be completely volatilized to form a solid (dried product) before use, or the dried product may be redissolved in an arbitrary solvent before use.
  • the squeezed liquid obtained by squeezing the raw material plant also contains the same active ingredient as the extract, the squeezed liquid can be used instead of the extract.
  • the APJ expression promoter of the present invention may consist of one or more crude drugs selected from the group consisting of Houttuynia cordata extract, Sakura leaf extract, and neem leaf extract, or may be contained as an active ingredient.
  • the skin elasticity improving agent of the present invention contains the APJ expression promoter of the present invention.
  • the skin elasticity improving agent of the present invention promotes APJ expression, and the promoted APJ acts on blood vessels to stabilize them, thereby promoting collagen synthesis around the blood vessels and improving skin elasticity. it can.
  • Improving skin elasticity means making the skin condition optimal, not too soft and not too hard.
  • it may be a condition such as swelling or edema
  • it may be a condition such as a lump, a lump, or a tumor. Therefore, although not limited, the human cheek as described in the examples.
  • Contact force centered on the average contact force of about 17.5 mN, for example, contact force in the range of about 10.0 mN to 22.0 mN, about 12.0 mN to 20.0 mN, or collagen corresponding to the contact force in such a range.
  • the storage elastic modulus in the range of Pa may be used. It is also known that the skin loses elasticity and becomes soft with aging.
  • improvement of skin elasticity means, for example, elasticity reduced due to aging, swelling, etc., for example, less than 5.0 mN, less than 6.0 mN, less than 7.0 mN, less than 8.0 mN, less than 9.0 mN, less than 10.0 mN, less than 11.0 mN, It may be increased from a contact force of less than 12.0 mN, less than 13.0 mN, less than 14.0 mN, less than 15.0 mN, less than 16.0 mN, less than 17.0 mN, or about 10.0 mN to 22.0 mN, about 12.0 mN to.
  • the current elasticity within the range of the appropriate value such as 20.0 mN may be further increased within the range of the appropriate value.
  • the increase may be, for example, a increase with a statistically significant difference in contact force or storage modulus with a significance level of 5% (eg, Student's t-test) and / or, for example, 10% or more. , 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, 100% or more.
  • the contact force or storage elastic modulus of the skin may be maintained within the above-mentioned appropriate value range.
  • Promotion of APJ expression may mean, for example, that the amount of mRNA or protein of APJ in a biological sample increases when the APJ expression promoter of the present invention is added, as compared with the case where it is not added.
  • the increase may be, for example, an increase with a statistically significant difference (eg, Student's t-test) with a significance level of 5%, and / or, for example, 10% or more, 20% or more, 30% or more,
  • the increase may be 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, 100% or more.
  • the APJ expression promoter and skin elasticity improving agent of the present invention may contain any one of the above active ingredients alone. , Two or more types may be contained in any combination and ratio.
  • the agent of the present invention may also be a composition in which the above-mentioned active ingredient is combined with one or more other ingredients such as excipients, carriers and / or diluents.
  • the composition and form of the composition are arbitrary, and may be appropriately selected according to conditions such as the active ingredient and use.
  • the composition can be produced by a conventional method with a formulation appropriately combined with an excipient, a carrier and / or a diluent and the like and other components according to the dosage form.
  • the agent of the present invention is appropriately used orally or parenterally (transdermal administration, intravenous administration, intraperitoneal administration, etc.), and may be administered by any route, but it acts on blood vessels of the skin. Percutaneous administration is preferred.
  • the agent of the present invention may be blended in cosmetics, pharmaceuticals, quasi-drugs, etc. and used for humans and animals, and may be blended in various foods and drinks, for example, dietary supplements such as supplements, and ingested by humans and animals. It may be administered to humans and animals as a pharmaceutical preparation.
  • the blending amount (dry mass) of the active ingredient such as the above extract depends on the type, purpose, form, usage method and the like. , Can be decided as appropriate.
  • about 0.000001% to 50.0% (dry mass conversion) of Jyuyaku extract, Sakura leaf extract, and neem leaf extract can be mixed in the total amount of cosmetics, and in particular, about 0.0001% to 10.0% (dry mass conversion). It may be added as follows.
  • ingredients usually used for skin external preparations such as cosmetics, pharmaceuticals, quasi-drugs, etc., such as antioxidants, oils, UV protection, within the range that does not impair the effects of the present invention.
  • Agents, surfactants, thickeners, alcohols, powder components, coloring materials, aqueous components, water, various skin nutrients and the like can be appropriately blended as needed.
  • metal ion blockers such as disodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, and gluconic acid, preservatives such as methylparaben, ethylparaben, and butylparaben, caffeine, tannin, Bellapamil, tranexamic acid and its derivatives, licorice extract, glabridin, hot water extract of carin fruit, various crude drugs, tocopherol acetate, glycyrrhizinic acid and its derivatives or salts thereof, vitamin C, magnesium ascorbate phosphate, Whitening agents such as ascorbic acid glucoside, arbutin, and kodiic acid, and sugars such as glucose, fructose, mannose, sucrose, and trehalose can also be appropriately added.
  • preservatives such as methylparaben, ethylparaben, and butylparaben, caffeine, tannin, Bellapamil
  • the external preparation for skin of the present invention is particularly preferably applicable as a cosmetic such as a cosmetic applied to the outer skin, a non-medicinal product, etc., and the dosage form is not limited as long as it can be applied to the skin.
  • Any dosage form such as solution system, solubilization system, emulsification system, powder dispersion system, water-oil two-layer system, water-oil-powder three-layer system, ointment, lotion, gel, aerosol, etc. is applied.
  • agent of the present invention is used as cosmetics, for example, face cream, massage cream, body cream, milky lotion, lotion, beauty essence, gel, pack, cleansing cream, hand cream, lotion, foundation, lipstick, lip balm, hand It may be used in the form of powder, body shampoo, bath cosmetics and the like.
  • the blending amount (dry mass) of the plant or its extract can be appropriately determined according to their types, purposes, forms, usage methods and the like. For example, it can be blended so that the daily intake of the plant or its extract for an adult is about 0.00001 mg to 10.0 g (dry residue) and about 0.001 mg to 5.0 g (dry residue).
  • the form of food and drink and feed can be any form, for example, granules, granules, pastes, gels, solids, or liquids. These forms include various known substances known to be contained in foods and drinks, such as binders, disintegrants, thickeners, dispersants, reabsorption promoters, emulsifiers, buffers, and surfactants. Excipients such as activators, solubilizers, preservatives, emulsifiers, tonicity agents, stabilizers and pH adjusters can be appropriately contained.
  • the dosage form is also arbitrary, such as oral solid preparations such as tablets, granules, powders and capsules, oral liquid preparations such as oral liquids and syrups, and parenteral liquid preparations such as injections.
  • the form of the above can be appropriately prepared by a known method. If it is an external preparation, it can be used in various forms such as lotions, suspensions / emulsions, liquids, ointments, and patches. These formulations include commonly used binders, disintegrants, thickeners, dispersants, reabsorption promoters, flavoring agents, buffers, surfactants, solubilizers, preservatives, emulsifiers, isotonic agents. , Excipients such as stabilizers and pH regulators may be used as appropriate.
  • the present invention also relates to a method for screening a skin elasticity improving agent using APJ expression in a biological sample as an index.
  • the screening method of the present invention is, for example, the following steps: culturing a biological sample in a medium containing a candidate drug; measuring APJ expression in the biological sample; and when APJ expression is increased as compared with a control.
  • the candidate drug as a substance having a skin elasticity improving effect;
  • the control is APJ expression when different in that it is cultured in a medium containing no candidate drug.
  • Experiments on controls may be performed in parallel with the screening method of the present invention or may be performed in advance.
  • the biological sample used in the screening method of the present invention is arbitrary, such as vascular endothelial cells and adipocytes, and is not limited as long as APJ expression can be measured.
  • vascular endothelial cells in a vascular model created by inducing angiogenesis from the subcutaneous adipos tissue of an animal such as a human vascular constituent cells such as pericytes may be used, and vascular endothelial cells obtained from a living body.
  • Pericytes, or passaged cells thereof, established cells, HUVEC, HAEC, HMVEC and the like may be used.
  • APJ-expressing cells may be used as described in Patent Documents 3 and 4.
  • a pre-culture step of culturing the biological sample as described above may be included before the step of culturing the biological sample in the medium containing the candidate drug.
  • angiogenesis may be induced from the subcutaneous adipose tissue to create a vascular model.
  • a post-culturing step of further culturing in the medium containing no candidate drug may be included.
  • the candidate drug or a diluted solution thereof may be directly added to the culture obtained in the pre-culture step and cultured, or the medium may be replaced with a medium containing the candidate drug. The culture may be carried out.
  • Measurement of APJ expression can be determined by measuring the amount of APJ mRNA or protein in a biological sample.
  • the amount of mRNA can be measured by using a method known in the present art such as quantitative PCR and Northern blotting.
  • a probe for APJ mRNA may be used.
  • the amount of protein can be determined using any technique known in the art such as Western blotting, immunostaining, FACS and the like.
  • an antibody that specifically binds to APJ may be used.
  • a screening system using APJ-expressing cells as described in Patent Documents 3 and 4 may be established and used.
  • the present invention also provides a kit for carrying out the screening method of the present invention, which comprises the above-mentioned reagents for determining APJ expression.
  • the substance having an APJ expression-promoting agent action screened by the screening method of the present invention may be any substance as long as it can promote the expression of APJ.
  • One aspect of the screening method of the present invention is to perform screening using an arbitrary library of cosmetic materials, food materials, pharmaceutical materials, etc., using APJ expression in a biological sample such as vascular endothelial cells as an index.
  • Examples of the substance having the APJ expression promoting action thus determined include one or more crude drugs selected from the group consisting of Houttuynia cordata extract, Sakura leaf extract, and neem leaf extract.
  • the present invention also relates to a method for improving skin elasticity, including application of an APJ expression promoter. If the skin elasticity is improved, it is expected that wrinkles and sagging will be improved.
  • the methods of improving skin elasticity herein relate to cosmetological methods for the purpose of cosmetology and can be distinguished from treatments performed by doctors and medical personnel. Such a beauty method may be performed individually, or may be performed at a beauty salon, a cosmetics store, an esthetic salon, or the like.
  • Experiment 1 Creation of 3D angiogenesis dermis model and visualization of vascular structure and produced collagen
  • a type I collagen gel solution was prepared using a collagen gel culture kit (Nitta gelatin). Specifically, in a 15 ml tube on ice, 2 ml of a 3 mg / ml cell matrix collagen solution was suspended in 2 ml of 1 mM dilute hydrochloric acid, and 500 ⁇ l of MEM concentrated 10-fold there and a collagen gel culture kit for neutralization. The attached C buffer was added with stirring at 500 ⁇ l. 100 ⁇ l of this solution was placed on a 35 mm glass-based dish (IWAKI) and incubated at 37 ° C for 30 minutes to gel.
  • IWAKI 35 mm glass-based dish
  • Primary antibodies include sheep anti-PECAM-1 / CD31 antibody (AF806, R & D systems, MN) against vascular endothelial cells, Cy3 ⁇ SMA antibody (c-6198, Sigma, MO) against pericite, and APJ.
  • Alexa Fluor594 Donkey anti-rabbit antibody R37119, Molecular Probes, Eugene, OR
  • Hoechst 33342 H3570, Invitrogen, CA
  • LSM880 Carl Zeiss, Germany
  • FIG. 1 shows the creation of a 3D angioplasty dermis model stained with anti-PECAM-1 / CD31 antibody.
  • FIG. 2 shows an angioplasty model stained with anti-PECAM-1 / CD31 antibody and anti-type I Collagen antibody.
  • FIG. 2 it was found that collagen is synthesized around the blood vessels.
  • collagen was found around the blood vessel, and in particular, a large amount of collagen was formed in the part considered to be the scaffold where the blood vessel will be elongated. Therefore, it is suggested that the presence of vascular structure contributes to collagen synthesis and, by extension, skin elasticity.
  • vascular endothelial cells were stained with sheep anti-Pecam-1 antibody (AF806, R & D systems, MN), and pericytes were stained with rabbit anti-NG2 antibody (Milipore).
  • Alexa Fluor 594 Donkey anti-sheep antibody A-11016, Molecular Probes, Eugene, OR
  • Alexa Fluor 488 Donkey anti-rabbit antibody A-21206, Molecular Probes, Eugene, OR
  • the sound velocity distribution image and the immunostaining image were superposed, and the sound velocity value in the range of 50 ⁇ m around the blood vessel was quantified.
  • 10 samples were used, and the circumference of 15 blood vessels per tissue was quantified. The results are shown in Figure 3. From FIG. 3, it can be seen that in the aged skin, the sound velocity value in the area around the blood vessels decreases significantly as the blood vessels decrease. In other words, it was suggested that the decrease in skin elasticity and the decrease in blood vessels in aging are related.
  • Experiment 3 Collagen gel hardness measurement A type I collagen gel solution having each concentration (0.24, 0.6, 0.9, 1.2, 1.8 mg / ml) was prepared on ice by the same method as in Experiment 1. Then, it was gelled in a 24-well plate at 37 degrees for 30 minutes to prepare a collagen gel. The stored elastic modulus (Pa) of the prepared collagen gel was measured using a Physica MCR 300 Modular Compact Rheometer (Anton Paar, Germany) to determine the hardness of the gel. The results are shown in Fig. 4. From FIG. 4, it can be seen that the collagen gel concentration and the storage elastic modulus have a corresponding relationship.
  • Experiment 5 Analysis of changes in vascular structure in response to collagen gel hardness
  • type I collagen gel (0.24, 0.9, 1.8 mg / ml) at each concentration was produced.
  • the gels at each of these concentrations had storage elastic moduli of 2.6 ⁇ 0.8, 14.0 ⁇ 5.4, and 48.1 ⁇ 17.0 (Pa), respectively.
  • 3D angiogenesis was induced from normal human subcutaneous adipose tissue by the same method as in Experiment 1. After culturing for 13 days, immunostaining was performed in the same manner as in Experiment 1 to visualize vascular endothelial cells and pericytes.
  • Fig. 6 The results are shown in Fig. 6. From Fig. 6, in the case of a low-concentration gel (0.24 mg / ml) with an elastic modulus of 2.6 ⁇ 0.8 Pa, thin and unstable blood vessels were formed, but at a higher concentration (0.9 mg / m), a high elastic modulus (14.0) was formed. In the case of the gel having ⁇ 5.4 Pa), thick and stable blood vessels were formed. However, in the case of a gel having a higher elastic modulus (48.1 ⁇ 17.0 Pa) at a higher concentration (1.8 mg / ml), on the contrary, many thin and unstable blood vessels were observed. From the results shown in FIG.
  • Experiment 6 Analysis of vascular cell expression factor (APJ) in response to collagen gel hardness Type I having each concentration (0, 0.12, 0.6, 0.9, 1.2, 1.8 mg / ml) in the same manner as in Experiment 1.
  • a collagen gel solution was prepared on ice.
  • Human umbilical cord blood venous endothelial cells (HUVEC) seeded at 10 5 cells / well on a 12-well plate were cultured to confluence, 300 ⁇ l / well of each type I collagen gel solution was added, and gelation was performed by incubating at 37 ° C. The cells were further cultured. After 6 hours of culturing, Trizol was added to each well to disrupt the cells. Chloroform extraction was performed from the obtained solution to obtain total RNA.
  • HUVEC Human umbilical cord blood venous endothelial cells
  • the concentration of the obtained total RNA was measured by nano drop and adjusted to 35 ng / ml with RNase free water. Thereafter, TaqMan TM RNA-to-C T TM 1-Step Kit (Applied Biosystems, CA) Taqman probe for human APJ mRNA (Hs00270873, Applied Biosystems, CA) was used to compare the mRNA expression level of APJ.
  • FIG. 7 The results are shown in Fig. 7.
  • the figure on the left is a graph showing the relationship between collagen gel concentration and APJ mRNA expression level. It was clarified that the APJ mRNA expression level reached its peak under the condition of 0.9 mg / ml collagen gel, and it was observed that the expression decreased in the low concentration or high concentration collagen gel. In other words, it can be seen that the expression of APJ changes in response to the physical properties of the surrounding environment such as the elasticity of the matrix. Such a relationship between physical properties and expression was not found in other vascular stabilizing factors such as Tie2 (data not shown), and was APJ-specific. In addition, the elasticity of the collagen gel derived in this experiment was almost the same as the gel concentration corresponding to normal human skin elasticity.
  • the right figure of FIG. 7 is a photomicrograph showing the localization of APJ in a vascular model formed in a collagen gel having a concentration of 0.9 mg / ml. It was found that APJ was localized in cell process sites such as filopodia extending from vascular endothelial cells toward the periphery, suggesting that APJ may directly sense the surrounding matrix environment and stabilize blood vessels. It was.
  • Experiment 7 Preparation of APJ high expression 3D angioplasty dermis model and structural analysis
  • a human APJ gene sequence was inserted into a pEGFP-N1 vector (Clontech, CA) to obtain an APJ high expression vector for lentivirus introduction.
  • APJ highly expressed lentivirus was prepared based on this vector (Oriental yeast).
  • a 3D angioplasty dermis model was created by the same method as in Experiment 1. Then, on the 21st day after the start of culturing, this model was transfected with APJ expression vector by lentivirus infection and cultured for 5 days.
  • a blood vessel model prepared under the same conditions except that transfection was not performed was cultured.
  • FIG. 9 skin elasticity and APJ expression interact with each other, and APJ acts as a sensor for skin elasticity to stabilize blood vessels and blood vessels. It is possible that there is a cycle in which collagen synthesis is promoted in the surroundings and fed back to skin elasticity. Therefore, it is considered that even if the skin has decreased elasticity due to aging or the like, it is possible to strengthen the cycle and improve the skin elasticity by enhancing APJ expression. Therefore, in the following experiments, substances having an APJ expression promoting action were screened.
  • Experiment 8 Screening method for substances having a skin elasticity improving effect that promotes APJ expression Screening was performed using a total of 49 kinds of raw materials including a plant extract that is said to have an anti-aging effect as a candidate drug.
  • Uses Juyaku extract (Juyaku extract ET-50) manufactured by Koei Kogyo Co., Ltd., Sakura Leaf extract (Falcolex Sakura Leaf B) manufactured by Ichimaru Falcos, and Neem Leaf Extract (Neem Leaf Liquid B) manufactured by Ichimaru Falcos did. These extracts were dissolved in dimethyl sulfoxide (DMSO) to prepare samples at a final concentration of 0.1% (w / w).
  • DMSO dimethyl sulfoxide
  • a DMSO solution free of these extracts was used as a control.
  • HUVEC seeded at 10 5 cells / well on a 12-well plate was cultured to confluence, the above sample was added to a final concentration of 0.1%, incubated at 37 ° C, and cultured for 4 hours, as in Experiment 6.
  • the mRNA expression level of APJ was compared by the method of.

Abstract

La présente invention concerne une substance qui améliore l'élasticité de la peau et un procédé de criblage de substances ayant une action d'amélioration de l'élasticité de la peau.　L'invention concerne un promoteur d'expression d'APJ et un agent qui est efficace pour améliorer l'élasticité de la peau par stabilisation vasculaire en utilisant ledit promoteur pour améliorer l'expression d'APJ. Le promoteur d'expression d'APJ, qui comprend une ou plusieurs substances médicamenteuses brutes choisies dans le groupe constitué par un extrait d'Houttuynia cordata, un extrait de feuille de cerisier et un extrait de feuille de neem, est efficace pour améliorer l'élasticité de la peau par stabilisation vasculaire. Un procédé de criblage selon la présente invention permet de sélectionner une substance ayant une action d'amélioration de l'élasticité de la peau.
PCT/JP2019/019573 2019-05-16 2019-05-16 Promoteur de l'expression d'apj WO2020230331A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201980096460.XA CN113825492A (zh) 2019-05-16 2019-05-16 Apj表达促进剂
JP2021519240A JPWO2020230331A1 (fr) 2019-05-16 2019-05-16
PCT/JP2019/019573 WO2020230331A1 (fr) 2019-05-16 2019-05-16 Promoteur de l'expression d'apj

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2019/019573 WO2020230331A1 (fr) 2019-05-16 2019-05-16 Promoteur de l'expression d'apj

Publications (1)

Publication Number Publication Date
WO2020230331A1 true WO2020230331A1 (fr) 2020-11-19

Family

ID=73289576

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/019573 WO2020230331A1 (fr) 2019-05-16 2019-05-16 Promoteur de l'expression d'apj

Country Status (3)

Country Link
JP (1) JPWO2020230331A1 (fr)
CN (1) CN113825492A (fr)
WO (1) WO2020230331A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090077619A (ko) * 2008-01-11 2009-07-15 (주)제이엠비 주름개선에 효과가 있는 한방추출물을 포함하는 화장료조성물
JP2013209348A (ja) * 2012-03-30 2013-10-10 Shiseido Co Ltd Ａｐｊ活性化剤
JP2013216646A (ja) * 2012-03-12 2013-10-24 Pola Chemical Industries Inc マトリックスメタロプロテアーゼ活性阻害剤及び抗菌ペプチド産生促進剤
JP2014094966A (ja) * 2010-02-10 2014-05-22 Oriza Yuka Kk Ａｇｅ産生抑制剤
KR20140097095A (ko) * 2014-07-22 2014-08-06 (주)아모레퍼시픽 피부의 볼륨 증가 촉진용 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170136911A (ko) * 2016-06-02 2017-12-12 주식회사 엘지생활건강 복합 생약 추출물을 포함하는 피부 개선용 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090077619A (ko) * 2008-01-11 2009-07-15 (주)제이엠비 주름개선에 효과가 있는 한방추출물을 포함하는 화장료조성물
JP2014094966A (ja) * 2010-02-10 2014-05-22 Oriza Yuka Kk Ａｇｅ産生抑制剤
JP2013216646A (ja) * 2012-03-12 2013-10-24 Pola Chemical Industries Inc マトリックスメタロプロテアーゼ活性阻害剤及び抗菌ペプチド産生促進剤
JP2013209348A (ja) * 2012-03-30 2013-10-10 Shiseido Co Ltd Ａｐｊ活性化剤
KR20140097095A (ko) * 2014-07-22 2014-08-06 (주)아모레퍼시픽 피부의 볼륨 증가 촉진용 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YOKOYAMA, YOKO ET AL.: "Inhibitory regulation of skin fibrosis in systemic sclerosis by apelin/APJ signaling", ARTHRITIS & RHEUMATOLOGY, vol. 70, no. 10, October 2018 (2018-10-01), pages 1661 - 1672, XP055760042 *

Also Published As

Publication number Publication date
CN113825492A (zh) 2021-12-21
JPWO2020230331A1 (fr) 2020-11-19

Similar Documents

Publication Publication Date Title
JP5628797B2 (ja) 人参の花または人参の種子抽出物を含有する皮膚外用剤組成物
AU2017385661B2 (en) Composition for prevention and treatment of muscular diseases or for improvement of muscle function containing 3,5-dicaffeoylquinic acid or chrysanthemum extract
JP2009051740A (ja) Ｎｆａｔシグナル阻害剤及びｎｆａｔシグナル阻害方法
TWI747280B (zh) 余甘子萃取發酵物及其製備與應用
WO2017022091A1 (fr) Agent contenant une substance attirant les cellules souches graisseuses pour remédier au relâchement ou au vieillissement cutané provoqué par la cavitation dermique
JP2012116765A (ja) Ｃｇｒｐ応答性促進剤
WO2020230331A1 (fr) Promoteur de l'expression d'apj
WO2010047103A1 (fr) Inhibiteur du signal de nfat et agent de croissance capillaire
WO2010146622A1 (fr) Inhibiteur du signal du nfat et inhibiteur de la calcineurine
KR20150063485A (ko) Vegfc 생산 촉진제
JP5253821B2 (ja) インテグリン、ビンキュリン促進剤及びナトリウム依存性ビタミンｃ輸送体（ｓｖｃｔ２）の発現促進剤
JP2019077643A (ja) Ｗｎｔ発現抑制剤
TWI740964B (zh) 促進脂肪細胞分化之用途及篩選促進脂肪細胞分化物質之方法
TW202042786A (zh) Apj表現促進劑
JP2024004964A (ja) Ａｐｊ発現促進剤
WO2022210296A1 (fr) Activateur de signal d'ocytocine et agent favorisant la prolifération des kératinocytes induite par l'ocytocine
KR102501845B1 (ko) 백수오 추출물을 유효성분으로 포함하는 피부 재생 또는 상처 치료용 조성물
JP2019516777A (ja) 美白剤
JP6017259B2 (ja) エンドセリン作用抑制剤
KR102359441B1 (ko) 지방세포 분화 촉진용 조성물 및 지방세포 분화 촉진 물질의 스크리닝 방법
JP2019533681A (ja) エンドセリン変換酵素阻害剤
JP2011178751A (ja) 美白剤
JP2021187789A (ja) ヒートショックプロテイン誘導剤、一酸化窒素産生促進剤、抗更年期障害剤、抗加齢剤、化粧品および食品または飲料
JP2020189826A (ja) ホスファチジルイノシトールを有効成分とする生理活性組成物
JP5547381B2 (ja) 育毛剤及びｎｆａｔシグナル阻害剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19928538

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021519240

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19928538

Country of ref document: EP

Kind code of ref document: A1